Joan Montero

Over the last years I pioneered a novel predictive biomarker for therapy response called dynamic BH3 profiling (DBP) initially developed at Dana-Farber Cancer Institute (DFCI), that has been patented (I am listed as co-inventor) and is currently used for precision medicine to find better treatments for different forms of cancer. Moreover, as Junior faculty - Instructor in Medicine at Dana-Farber Cancer Institute/Harvard Medical School/ Brigham and Women’s Hospital I found a new treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematological malignancy that affects mostly to the skin, now explored in a clinical trial. During my scientific career I have trained other scientists: undergraduate students, Harvard graduate students and international medica